EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder

Sean J Pittock, Michael Barnett, Jeffrey L Bennett, Achim Berthele, Jérôme de Sèze, Michael Levy iD, Ichiro Nakashima iD, Celia Oreja-Guevara iD, Jacqueline Palace, Friedemann Paul iD, Carlo Pozzilli, Marcus Yountz und 3 weitere

Annals of Neurology · 2023-06 · 93 (6) · 1053-1068

DOI: 10.1002/ana.26626 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 05.04.2023. Verfasst von Sean J Pittock und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Neuromyelitis Optica. Die Arbeit wurde bisher 229-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Alexion Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

CHAMPION‐NMOSD (NCT04201262) is a phase 3, open‐label, externally controlled interventional study evaluating the efficacy and safety of the terminal complement inhibitor ravulizumab in adult patients with anti–aquaporin‐4 antibody–positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD). Ravulizumab binds the same complement component 5 epitope as the approved therapeutic eculizumab but has a longer half‐life, enabling an extended dosing interval (8 vs 2 weeks).

Methods

The availability of eculizumab precluded the use of a concurrent placebo control in CHAMPION‐NMOSD; consequently, the placebo group of the eculizumab phase 3 trial PREVENT (n = 47) was used as an external comparator. Patients received weight‐based intravenous ravulizumab on day 1 and maintenance doses on day 15, then once every 8 weeks. The primary endpoint was time to first adjudicated on‐trial relapse.

Results

The primary endpoint was met; no patients taking ravulizumab (n = 58) had an adjudicated relapse (during 84.0 patient‐years of treatment) versus 20 patients with adjudicated relapses in the placebo group of PREVENT (during 46.9 patient‐years; relapse risk reduction = 98.6%, 95% confidence interval = 89.7%–100.0%, p < 0.0001). Median (range) study period follow‐up time was 73.5 (11.0–117.7) weeks for ravulizumab. Most treatment‐emergent adverse events were mild/moderate; no deaths were reported. Two patients taking ravulizumab experienced meningococcal infections. Both recovered with no sequelae; one continued ravulizumab treatment.

Interpretation

Ravulizumab significantly reduced relapse risk in patients with AQP4+ NMOSD, with a safety profile consistent with those of eculizumab and ravulizumab across all approved indications. ANN NEUROL 2023;93:1053–1068

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuromyelitis OpticaAdultHumansAquaporin 4Complement Inactivating AgentsRecurrenceAntibodies, Monoclonal, Humanized

Substanzen

Aquaporin 4Complement Inactivating AgentsravulizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.
  • Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
  • Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • Departments of Neurology and Ophthalmology, Programs in Neuroscience and Immunology, University of Colorado, Aurora, CO, USA.
  • Department of Neurology, School of Medicine, Technical University of Munich, Munich, Germany.
  • Department of Neurology and Clinical Investigation Center, Strasbourg University Hospital Center, Strasbourg, France.

ORCID-Profile: Michael Levy, Ichiro Nakashima, Celia Oreja-Guevara, Friedemann Paul

Förderung

  • Alexion Pharmaceuticals

Zitieren

APA

Pittock, S. J., Barnett, M., Bennett, J. L., Berthele, A., de Sèze, J., Levy, M., Nakashima, I., Oreja-Guevara, C., Palace, J., Paul, F., Pozzilli, C., Yountz, M., Allen, K., Mashhoon, Y., & Kim, H. J. (2023). Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder. Annals of Neurology, 93(6), 1053-1068. https://doi.org/10.1002/ana.26626

Vancouver

Pittock SJ, Barnett M, Bennett JL, Berthele A, de Sèze J, Levy M, et al. Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder. Annals of Neurology. 2023;93(6):1053-1068. doi:10.1002/ana.26626

BibTeX
@article{Pittock2023,
  author = {Pittock, Sean J and Barnett, Michael and Bennett, Jeffrey L and Berthele, Achim and de Sèze, Jérôme and Levy, Michael and Nakashima, Ichiro and Oreja-Guevara, Celia and Palace, Jacqueline and Paul, Friedemann and Pozzilli, Carlo and Yountz, Marcus and Allen, Kerstin and Mashhoon, Yasmin and Kim, Ho Jin},
  title = {Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder},
  journal = {Annals of Neurology},
  year = {2023},
  volume = {93},
  number = {6},
  pages = {1053--1068},
  doi = {10.1002/ana.26626}
}
Kostenlos starten →